Applied Molecular Transport Announces Positive Top-Line Phase II Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Applied Molecular Transport, Inc. announced positive top-line Phase II results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and no current FDA-approved therapies.